Press Releases
- Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
May 18, 2012, 9:35 AM EDT - Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington's and Parkinson's Diseases
May 16, 2012, 9:35 AM EDT - Intellect Neurosciences Issues Letter to Shareholders
May 15, 2012, 9:35 AM EDT - Intellect Neurosciences Adds Two New Tau Programs to its Alzheimer's Disease Development Pipeline
May 7, 2012, 9:35 AM EDT - Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
Apr 17, 2012, 9:15 AM EDT - Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN® Alzheimer's Disease Immunotherapy Technology Platform
Mar 6, 2012, 8:30 AM EST - Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
Feb 14, 2012, 8:35 AM EST - Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in Treatment of Alzheimer's disease
Feb 7, 2012, 8:30 AM EST - Intellect Neurosciences Issues Letter to Shareholders
Feb 2, 2012, 1:44 PM EST - Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
Jan 17, 2012, 9:35 AM EST
